Dr Reddys Laboratories Ltd (DRREDDY) Q4FY26 Management Mirror - Mar-2026 Qtr
Margins & Profitability
Management expects FY27 gross margins to exceed 50%, targeting a 50% to 55% range driven by product cost improvements and new launches, tracking consistently with the Dec'25 Qtr guidance of 50% to 55% post-Lenalidomide normalization and the Sep'25 Qtr goal of returning to historical margins; furthermore, base EBITDA margins are targeted at 20%, potentially reaching 25% with semaglutide contributions. [Status: Reaffirmed]
5 more themes on the ELITE plan.